All In Biotech

Drug Trial Radar · NCT03425643

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 797 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

797

Actual

Start

Apr 24, 2018

Primary completion

Jul 10, 2023

Study completion Oct 15, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS).

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • PembrolizumabBiological

    200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

  • PlaceboDrug

    Normal saline by IV infusion Q3W, given on cycle day 1.

  • CisplatinDrug

    75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

  • GemcitabineDrug

    1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.

  • PemetrexedDrug

    500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event Free Survival (EFS)Time frame: Up to approximately 5 years
  2. Overall Survival (OS)Time frame: Up to approximately 5 years

Locations

227 sites in 25 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center ( Site 0028)

    Gilbert, Arizona

  • Western Regional Medical Center, Inc. ( Site 0050)

    Goodyear, Arizona

  • University of Arizona Cancer Center - Dignity Health ( Site 0062)

    Phoenix, Arizona

  • University of Arizona Cancer Center ( Site 0012)

    Tucson, Arizona

  • Pacific Cancer Medical Center, Inc. ( Site 0004)

    Anaheim, California

  • Providence Saint Joseph Medical Center ( Site 0061)

    Burbank, California

  • Pacific Cancer Care ( Site 0035)

    Monterey, California

  • John Wayne Cancer Institute ( Site 0049)

    Santa Monica, California

  • St Joseph Heritage Healthcare ( Site 0040)

    Santa Rosa, California

  • Stanford University, Stanford Cancer Center ( Site 0046)

    Stanford, California

  • Hartford Hospital ( Site 0069)

    Hartford, Connecticut

  • Helen F. Graham Cancer Center & Research Institute ( Site 0015)

    Newark, Delaware

  • Mayo Clinic Jacksonville ( Site 0022)

    Jacksonville, Florida

  • Miami Cancer Institute-Baptist Hospital ( Site 0068)

    Miami, Florida

  • Southeastern Regional Medical Center ( Site 0051)

    Newnan, Georgia

  • Northwest Oncology and Hematology ( Site 0001)

    Elk Grove Village, Illinois

  • Ingalls Memorial Hospital ( Site 0044)

    Harvey, Illinois

  • PPG-Oncology ( Site 0043)

    Fort Wayne, Indiana

  • University of Iowa Hospital and Clinics ( Site 0010)

    Iowa City, Iowa

  • Ashland-Bellefonte Cancer Center ( Site 0021)

    Ashland, Kentucky

  • Harry & Jeanette Weinberg Cancer Institute ( Site 0081)

    Baltimore, Maryland

  • Boston Medical Center ( Site 0057)

    Boston, Massachusetts

  • UMass Memorial Medical Center ( Site 0030)

    Worcester, Massachusetts

  • Henry Ford Health System ( Site 0031)

    Detroit, Michigan

  • Herbert Herman Cancer Center, Sparrow Hospital ( Site 0034)

    Lansing, Michigan

  • Mayo Clinic ( Site 0026)

    Rochester, Minnesota

  • St. Vincent Healthcare Frontier Cancer Center ( Site 0005)

    Billings, Montana

  • University of Nebraska Medical Center ( Site 0047)

    Omaha, Nebraska

  • Memorial Sloan Kettering Cancer Center Basking Ridge ( Site 0074)

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0077)

    Middletown, New Jersey

  • MSKCC-Bergen ( Site 0075)

    Montvale, New Jersey

  • St. Peter's Hospital Cancer Care Center ( Site 0039)

    Albany, New York

  • Memorial Sloan-Kettering Cancer Center at Commack ( Site 0076)

    Commack, New York

  • Memorial Sloan Kettering Cancer Center Westchester ( Site 0079)

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center ( Site 0060)

    New York, New York

  • Stony Brook University Medical Center - Cancer Center ( Site 0019)

    Stony Brook, New York

  • Montefiore Einstein Center ( Site 0016)

    The Bronx, New York

  • Memorial Sloan Kettering Cancer Center - Nassau ( Site 0078)

    Uniondale, New York

  • White Plains Hospital Center for Cancer Care ( Site 0007)

    White Plains, New York

  • Southwestern Regional Medical Center, Inc. ( Site 0054)

    Tulsa, Oklahoma

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.